BioNTech SE (NASDAQ:BNTX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of BioNTech SE (NASDAQ:BNTX) have been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $135.54.

A number of research firms have commented on BNTX. JPMorgan Chase & Co. upgraded shares of BioNTech from an “underweight” rating to a “neutral” rating and increased their price objective for the company from $91.00 to $125.00 in a research note on Monday, September 16th. HSBC boosted their target price on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, September 19th. HC Wainwright lifted their price target on BioNTech from $113.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Finally, Hsbc Global Res upgraded shares of BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BNTX. GAMMA Investing LLC grew its holdings in BioNTech by 21.7% during the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after purchasing an additional 111 shares during the last quarter. Covestor Ltd grew its stake in shares of BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares during the last quarter. Midwest Professional Planners LTD. raised its position in shares of BioNTech by 7.2% during the first quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company’s stock worth $293,000 after acquiring an additional 212 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of BioNTech by 2.3% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 9,800 shares of the company’s stock valued at $904,000 after purchasing an additional 223 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after acquiring an additional 252 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Down 1.4 %

Shares of NASDAQ:BNTX opened at $111.48 on Friday. The stock has a 50-day simple moving average of $109.72 and a 200-day simple moving average of $95.77. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. The stock has a market capitalization of $26.51 billion, a P/E ratio of -49.33 and a beta of 0.24.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The firm had revenue of $128.70 million during the quarter, compared to analyst estimates of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The firm’s revenue was down 23.3% compared to the same quarter last year. During the same period last year, the business earned ($0.86) EPS. Equities analysts forecast that BioNTech will post -2.93 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.